Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SII Bivalent
- Development stage
- Discontinued
- Lead developer
- Novavax
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
SII Bivalent is a bivalent vaccine developed by Novavax. It is designed to provide immunity against SARS-CoV-2 by containing antigens from both the ancestral strain of SARS-CoV-2 and the B.1.351 (Beta) variant. The vaccine is adjuvanted with Matrix-M1 adjuvant to enhance the immune response. It is administered via intramuscular injection.
02
Targets
ACE2 (Angiotensin-converting enzyme 2)SARS-CoV-2 spike
Beyond the preview
Go deeper on SII Bivalent.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SII Bivalent.